홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Rifamycin

HCID 6324616
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
6998-60-3
표준 SMILES
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
InChIKey
HJYYPODYNSCCOU-ODRIEIDWSA-N
분자식
C37H47NO12
평균 분자량
697.8 g/mol
단동위원소 질량
697.30982593

개요

Rifamycin SV is a member of the class of rifamycins that exhibits antibiotic and antitubercular properties. It has a role as an antitubercular agent, an antimicrobial agent and a bacterial metabolite. It is a lactam, a polyphenol, a member of rifamycins, an organic heterotetracyclic compound, an acetate ester, a macrocycle and a cyclic ketal. It is a conjugate acid of a rifamycin SV(1-).

이름 및 식별자

우선 이름
Rifamycin
IUPAC
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
영어명
RIFAMYCIN SV
분자식
C37H47NO12
분자량
697.77

이름 및 동의어

RIFAMYCINRifamycin SVRifamicine SVRifomycin SVRifamicinaRifamycine6998-60-3RifamycinumRifocynRIFOMYCINDU69T8ZZPADTXSID1032014
이름 더 보기
rifocinrifamicinesvRIFAMYCIN INNRifamycin S-NaRifamycin (9CI)RIFAMYCIN SV USP/EP/BPRifaximin EP Impurity CRifaximin impurity C (EP)
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetateCHEBI:29673Rifamycin SV, an antibiotic produced by certain strains of Streptomyces mediterranei, or the same substance produced by any other meansRifamycine Chibret5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione 21-acetate((7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo(23.3.1.14,7.05,28)triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl) acetate(7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo(23.3.1.1^(4,7).0^(5,28))triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate(7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate

물성

구조 계산 물성보충 중

XLogP
4.9
극성 표면적
201 Ų
수소 결합 공여자 수
6
수소 결합 수용자 수
12
회전 가능 결합 수
3
무거운 원자 수
50
형식 전하
0
복잡도
1,330

실험 및 물리화학적 성질

LipidsPolyketides [PK] -> Ansamycins and related polyketides [PK05]
SolubilityInsoluble
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Gastrointestinal Agents; Rifamycins
Endocrine DisruptorsPotential endocrine disrupting compound
Dissociation Constants1.8

물리화학적 성질

녹는점
300 ° · 300° (dec 140°)
끓는 점
701.9 °C · 701.9°C (rough estimate)
밀도
1.2275 · 1.2275 (rough estimate)
굴절률
1.535 · 1.5350 (estimate)
산도 계수 (pKa)
5.17 · 5.17±0.70(Predicted)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

유해성 정보

Other Safety InformationIMAP assessments - Rifamycin: Environment tier I assessment

독성 정보

Hepatotoxicity · 1건

In prelicensure controlled trials in patients with traveler’s diarrhea, rates of serum ALT elevations were similar in subjects treated with rifamycin compared to placebo or comparator agent (ciprofloxacin) and no participants developed clinically apparent liver injury. Since its approval, there have been no published reports of hepatotoxicity attributed to rifamycin. Because of its minimal absorption rifamycin is considered unlikely to cause liver injury.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

독성
LD50 in mice (mg/kg): 550 i.v.; 625 i.p.; 2120 orally (Bergamini, Fowst)

화학 및 산업

약리 정보

ATC Code · 6건

J04AB03

A - Alimentary tract and metabolism

S - Sensory organs

S - Sensory organs

J - Antiinfectives for systemic use

D - Dermatologicals

Protein BindingThe protein binding of rifamycin is of about 80-95%.
Pharmacodynamics · 1건

Rifamycin is known to be effective against Gram-positive and Gram-negative pathogens and mycobacteria. It is very effective against _E. coli_ reporting a MIC90 of 64-128 mcg/ml without showing cross-resistance with other antimicrobial agents. The specific indication of rifamycin is extremely important as ther were previous reports that indicated a high risk factor in the generation of resistant _E. coli_ strains in patients with inflammatory bowel disease. In clinical trials, rifamycin was tested in a randomized clinical trial of travellers' coming from Mexico and Guatemala. In this trial, rifamycin was proven to significantly reduce the symptoms of travellers' diarrhea.

Mechanism of Action · 1건

Rifamycins, as well as all the other members of this group, present an antibacterial mechanism of action related to the inhibition of RNA synthesis. This mechanism of action is done by the strong binding to the DNA-dependent RNA polymerase of prokaryotes. The inhibition of the RNA synthesis is thought to be related with the initiation phase of the process and to involve stacking interactions between the naphthalene ring and the aromatic moiety in the polymerase. As well, it has been suggested that the presence of zinc atoms in the polymerase allows for the binding of phenolic -OH groups of the naphthalene ring. In eukaryotic cells, the binding is significantly reduced making them at least 100 to 10,000 times less sensitive to the action of rifamycins. The members of the rifamycin family present the same mechanism of action and the structural modifications are usually related to pharmacokinetic properties as well as to the interaction with eukaryotic cells.

Biological Half-LifeThe reported half-life when a dose of 250 mg of rifamycin was administered is 3 h.

관련 반응

4건
반응 기록 만들기
HRID 46717 반응식
HRID 46717반응물로
HRID 1388495 반응식
HRID 1388495생성물로
HRID 1388496 반응식
HRID 1388496생성물로
HRID 1415408 반응식
HRID 1415408생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
6998-60-3
PubChem CID
6324616
DTXSID
DTXSID1032014
ChEMBL
CHEMBL437765
ChEBI
CHEBI:29673
UNII
DU69T8ZZPA
EC Number
230-273-3
Metabolism/Metabolites
When absorbed, rifamycin is mainly metabolzied in hepatocytes and intestinal microsomes to a 25-deacetyl metabolite.
FDA Pharmacological Classification · 5건

DU69T8ZZPA

RIFAMYCIN

Established Pharmacologic Class [EPC] - Rifamycin Antibacterial

Chemical Structure [CS] - Rifamycins

Rifamycin is a Rifamycin Antibacterial.

MeSH Pharmacological Classification · 2건

Drugs that are used to treat RHEUMATOID ARTHRITIS.

Substances that inhibit the growth or reproduction of BACTERIA.

Absorption, Distribution and Excretion · 4건

Rifamycin has a very poor absorption and thus, the generation of an oral modified-release formulation using the technology of the multi-matrix structure was required for the generation of the FDA approved product. This preparation allows the delivery of the active ingredient in the distal small bowel and colon without interfering with the flora in the upper gastrointestinal tract. The multi-matrix is made by a lipophiic matrix surrounded in a hydrophilic matrix which allows for the protection of the active ingredient from dissolution in the intestinal aqueous fluids before it arrives in the cecum. All this matrix is surrounded by a gastro-resistant polymer that only desintegrate in a pH lower than 7. All this administration-customed formulation allows for a bioavailability of <0.1% and the plasma concentrations are reported to be of <2 ng/ml in patients receiving a dose of 400 mg. This confirms that the site of action of rifamycin stays in the small intestine and colon which prevents the need for dose adjustments in special populations as well as systemic drug interactions. The reported Cmax, tmax, AUC and mean residence time after a dosage of 250 mg of rifamycin is 36 mg/L, 5 min, 11.84 mg.h/L and 0.49 h respectively.

From the administered dose, 18%, 50% and 21% is recovered in feces during the first 24, 48 and 72h after administration. This will represent about 90% of the administered dose eliminated by the feces while the urinary secretion is negligible.

The reported volume of distribution after measured after a dosage of 250 mg of rifamycin is 101.8 L.

The reported clearance when a dose of 250 mg of rifamycin was administered is 23.3 L/h.

응용 분야 · 1건

용도Rifogal (Rifaximin EP Impurity C NA) is a antibacterial drug which functions by inhibiting bacterial RNA polymerase (RNAP), is an important part of the antibacteral armamentarium. Also, it is one of the few drugs in a multidrug regimens for treating lung disease (LD) due to Mycobacterium avium complex (MAC).

상·하류 제품 정보

하류 제품

Rifamycin Sodium

추가 설명

정의ChEBI: A member of the class of rifamycins that exhibits antibiotic and antitubercular properties.